Bibliografía
(1) Annese, V., Beaugerie, L., Egan, L., et al. (2015). European evidence-based consensus: inflammatory bowel disease and malignancies. Journal of Crohn's and Colitis, 9(11), 945-965.
(2) Yamane, L., Scapulatempo-Neto, C., Reis, R. M., et al. (2014). Serrated pathway in colorectal carcinogenesis. World journal of gastroenterology: WJG, 20(10), 2634-2640.
(3) Orlowska, J. (2013). Serrated lesions and hyperplastic (serrated) polyposis relationship with colorectal cancer: classification and surveillance recommendations. Gastrointestinal endoscopy, 77(6), 858-871.
(4) Feuerstein, J. D., Flier, S. N., Yee, E. U., et al. (2014). A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndrome. Journal of Crohn's and Colitis, 8(12), 1735-1739..
(5) Srivastava, A., Redston, M., Farraye, F. A., et al. (2008). Hyperplastic/serrated polyposis in inflammatory bowel disease: a case series of a previously undescribed entity. The American journal of surgical pathology, 32(2), 296-303.
(6) Carballal, S., Rodríguez-Alcalde, D., Moreira, L., et al. (2015). Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut, gutjnl-2015.
(7) Boparai, K. S., Mathus-Vliegen, E. M., Koornstra, J. J., et al. (2009). Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut.
(8) Johnson, D. H., Khanna, S., Smyrk, T. C., et al. (2014). Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. Alimentary pharmacology & therapeutics, 39(12), 1408-1417.
(9) Rivero-Sanchez, L., Lopez-Ceron, M., Carballal, S., et al. (2017). Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. Endoscopy, 49(01), 44-53.
(10) Subramanian, V., Mannath, J., Ragunath, K., et al. (2011). Meta‐analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Alimentary pharmacology & therapeutics, 33(3), 304-312.